Endocannabinoid System in Polycystic Kidney Disease
Observational studyHumans
- Design
- Observational study
- Subjects
- 102 patients with autosomal dominant polycystic kidney disease and 100 healthy subjects
- Dose used in the study
- Not stated in the abstract; no treatment was given
- Duration
- Baseline and after 2 and 4 years
- What was measured
- Plasma endocannabinoids and related lipids including palmitoylethanolamide by mass spectrometry; interleukins; kidney volume and eGFR change over time.
What the authors reported
Patients had higher IL-6 and IL-1b and lower plasma AEA, 2-AG and related lipids than healthy people. Baseline AEA was negatively associated with kidney volume growth and positively with change in kidney function, and palmitoylethanolamide was positively associated with yearly change in eGFR.
Limits of this study
An observational cohort that measured natural palmitoylethanolamide; it did not test PEA as a treatment and cannot show cause. Conflict of interest: none stated.
Source
PubMed 35263737 · doi:10.1159/000522113
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.